## Thomas W Lycan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2143301/publications.pdf

Version: 2024-02-01

40 509 12 22 papers citations h-index g-index

41 41 41 752 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Local control outcomes for combination of stereotactic radiosurgery and immunotherapy for non-small cell lung cancer brain metastases. Journal of Neuro-Oncology, 2022, 157, 101-107.	2.9	19
2	Team-Based Hospice Referrals: A Potential Quality Metric for Lung Cancer in the Immunotherapy Era. American Journal of Hospice and Palliative Medicine, 2022, , 104990912210917.	1.4	0
3	<i>SMARCA4</i> mutations in <i>KRAS</i> â€mutant lung adenocarcinoma: a multiâ€cohort analysis. Molecular Oncology, 2021, 15, 462-472.	4.6	29
4	What Oncologists Want: Identifying Challenges and Preferences on Diagnosis Data Entry to Reduce EHR-Induced Burden and Improve Clinical Data Quality. JCO Clinical Cancer Informatics, 2021, 5, 527-540.	2.1	4
5	Impact of age and frailty markers on overall survival among hospitalized patients with lung cancer treated with immunotherapy Journal of Clinical Oncology, 2021, 39, e21151-e21151.	1.6	O
6	Just-in-Time Teaching (JiTT) Screencasts: a Randomized Controlled Trial of Asynchronous Learning on an Inpatient Hematology-Oncology Teaching Service. Journal of Cancer Education, 2021, , 1.	1.3	0
7	Prevalence of DNA Repair Gene Mutations in Blood and Tumor Tissue and Impact on Prognosis and Treatment in HNSCC. Cancers, 2021, 13, 3118.	3.7	11
8	Chemoradiotherapy with highâ€dose cisplatin compared with weekly cisplatin for locally advanced head and neck squamous cell carcinoma. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 796-805.	1.8	2
9	Unmet Care Needs and Financial Hardship in Patients With Metastatic Non–Small-Cell Lung Cancer on Immunotherapy or Chemoimmunotherapy in Clinical Practice. JCO Oncology Practice, 2021, 17, e1110-e1119.	2.9	15
10	Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 5733.	3.7	13
11	Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non–Small-Cell Lung Cancer in Clinical Practice. Clinical Lung Cancer, 2020, 21, 255-263.e4.	2.6	28
12	Nicotine promotes brain metastasis by polarizing microglia and suppressing innate immune function. Journal of Experimental Medicine, 2020, 217, .	8.5	56
13	Serious Illness Conversations. Mayo Clinic Proceedings, 2020, 95, 2042-2043.	3.0	2
14	Adverse Event Reporting at Professional Conferences: We Need Better Standards and Bigger Posters. Journal of Thoracic Oncology, 2020, 15, 1394-1396.	1.1	0
15	Workflow Differences Affect Data Accuracy in Oncologic EHRs: A First Step Toward Detangling the Diagnosis Data Babel. JCO Clinical Cancer Informatics, 2020, 4, 529-538.	2.1	14
16	Neuromuscular ultrasound for taxane peripheral neuropathy in breast cancer. Muscle and Nerve, 2020, 61, 587-594.	2.2	12
17	Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non–Small-Cell Lung Cancer, 2020, 21, e286-e293.	2.6	22
18	End-of-life care in the immune checkpoint inhibitor era Journal of Clinical Oncology, 2020, 38, e24003-e24003.	1.6	0

#	Article	IF	Citations
19	Machine learning for prospective identification of immunotherapy related adverse events (irAEs) Journal of Clinical Oncology, 2020, 38, e14064-e14064.	1.6	0
20	Just-in-Time Teaching (JiTT) screencasts for the resident inpatient oncology service: A pilot study evaluating feasibility and effectiveness Journal of Clinical Oncology, 2020, 38, 11025-11025.	1.6	0
21	Just-in-Time Teaching (JiTT) Screencasts: A Randomized Controlled Trial of Asynchronous Learning on an Inpatient Hematology-Oncology Service. Blood, 2020, 136, 6-6.	1.4	O
22	251â€Factors evaluated as predictors of exceptional response to PD-1 inhibitors in patients with head and neck squamous cell cancer. , 2020, , .		0
23	Oral squamous cell cancer in a patient with Lynch syndrome. Oral Oncology, 2019, 97, 137-138.	1.5	1
24	Human papillomavirus-associated squamous cell carcinoma of the larynx or hypopharynx: Clinical outcomes and implications for laryngeal preservation. Oral Oncology, 2019, 98, 20-27.	1.5	24
25	Limited-Stage Small Cell Lung Cancer: Is Prophylactic Cranial Irradiation Necessary?. Practical Radiation Oncology, 2019, 9, e599-e607.	2.1	21
26	An evidenceâ€based medicine approach for case presentations by trainees. Clinical Teacher, 2019, 16, 575-579.	0.8	1
27	Single agent immunotherapy for relapsed or refractory small cell lung cancer (rrSCLC) Journal of Clinical Oncology, 2019, 37, e20094-e20094.	1.6	0
28	Non-invasive assessment of chemotherapy-induced peripheral neuropathy using neuromuscular ultrasound in breast cancer patients Journal of Clinical Oncology, 2019, 37, e23152-e23152.	1.6	0
29	Who is at risk for palliative care misconceptions and how do we address them? A mixed-methods study of metastatic lung cancer patients Journal of Clinical Oncology, 2019, 37, 67-67.	1.6	0
30	Severe neurologic complications of immune checkpoint inhibitors: a single-center review. Journal of Neurology, 2018, 265, 1636-1642.	3.6	49
31	Prognostic understanding and barriers to palliative care in patients with metastatic lung cancer on immunotherapy Journal of Clinical Oncology, 2018, 36, 36-36.	1.6	4
32	The spatial distribution of brain metastasis Journal of Clinical Oncology, 2018, 36, e14000-e14000.	1.6	0
33	Neuromuscular ultrasound for assessment of peripheral neuropathy in breast cancer patients receiving taxane therapy Journal of Clinical Oncology, 2018, 36, e22083-e22083.	1.6	1
34	Discovery of a predictive protein biomarker for leptomeningeal disease after craniotomy and radiation Journal of Clinical Oncology, 2018, 36, 2068-2068.	1.6	1
35	Impact of Curriculum Content on Resident Attitudes Towards Cancer Care. Journal of Cancer Education, 2017, 32, 280-282.	1.3	5
36	Sociodemographic predictors of patients with brain metastases treated with stereotactic radiosurgery. Oncotarget, 2017, 8, 101005-101011.	1.8	12

#	Article	IF	CITATION
37	A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PLoS ONE, 2016, 11, e0164244.	2.5	43
38	Pilot study of first-in-class antimitochondrial metabolism agent, CPI-613, as salvage monotherapy for small cell lung cancer Journal of Clinical Oncology, 2016, 34, e20100-e20100.	1.6	0
39	Lack of energy compensation over 4 days when white button mushrooms are substituted for beef. Appetite, 2008, 51, 50-57.	3.7	31
40	Efficacy of Meal Replacements Versus a Standard Food-Based Diet for Weight Loss in Type 2 Diabetes A Controlled Clinical Trial. The Diabetes Educator, 2008, 34, 118-127.	2.5	89